High-activity companies

The next major discovery in this field, which was the result of a joint research effort in 1968 between M and T Chemicals, Inc., and the Dow Chemical Company in the United States (475, 524), was that tricyclo-hexyltin hydroxide ("Plictran ) possesses a very high activity against certain types of mites, and this compound was subsequently introduced by Dow as an acaricide for use on apple, pear, and citrus-fruit trees. A second triorganotin acaricide, bis(trineophyltin) oxide ("Vendex or "Torque ), has recently been introduced by Shell Chemical Company (476). Two other tricyclohexyltin compounds are currently under de-... 

LSBC is highly active in protein and peptide commercialization, placing special emphasis on the development of protein therapeutics. LSBC s capabilities are two-fold, in one side, the company s protein expertise and in the other it s commercial-scale manufacturing in the plant-made bioprocessing. 

LIPP-SHAC [Liquid polymerization of propylene with super high activity catalyst] A process for making polypropylene. Developed by the Shell Chemical Company and used at Pemis, The Netherlands Carrington, England and Geelong, Australia. 

Nanotechnology is an evolving research area especially in materials and biotechnological sciences. First studies have shown that the special properties of nanoparticles can give rise to highly active and selective catalysts to enable chemists to perform entirely novel transformations. Discussion and evaluation of the potential of nanoparticles for chemical research in a pharmaceutical company with experts in the field was needed. Other areas in catalysis like biotransformations and metal catalyst screening and development continue to expand the possibilities for the manufacturing of test compounds and development candidates. 

During the last decade the design of potent FTIs has been the focus at a significant number of pharmaceutical companies and academic research institutions, as tools to better understand biology or as cUnical candidates, and has led to the synthesis of thousands of highly active compounds (some of them have already been cited in the preceding sections). It will not be possible to exhaustively review all these inhibitors, but we will rather focus on key examples and compounds that have reached the cUnical development phase. 

Bayer thus developed at approximately the same time as two other companies (Kyorin and Warner-Lambert) the highly active compound 7-(3-amino-l-pyrrolidi-nyl) - 8-chloro-1 -cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- 3-quinolinecarboxylic acid... 

One wonders what the conclusions would have been if a few dozen other known antiviral agents had been Incorporated In Bauer s study. Various pharmaceutical companies still have a number of agents not yet reported In the literature for example, Smith Kline French Laboratories has a compound or compounds highly active against a number of rhinoviruses In cell culture systemsWithout information on a number of such compounds, analysis at this time seems premature. 

There then followed a period of high activity when many pharmaceutical companies initiated studies to develop KCAs, principally of the benzopyran based series. 

---